Global Acyclovir Drug Market 2022 Trends, Analysis, Growth, Opportunities, Forecast to 2028

The global acyclovir drug market is anticipated to grow at a significant CAGR during the forecast period (2022- 2028). Acyclovir drug is an antiviral medication that is used to treat infections caused by the herpes simplex virus. There are also a few side effects caused by them such as nausea and diarrhea. The introduction of nanotechnology to develop antiviral medication, an increase in the prevalence of viral diseases, and technological advancements in the development of antiviral medications are certain factors that are driving the market growth. However, the high cost of antiviral drugs and stringent regulatory approvals are some factors restraining the market growth.

Scope of the Global Acyclovir Drug Report

The research study analyzes the Global Acyclovir Drug industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis

o Import and Export Overview

o Volume Analysis

o Current Market Trends and Future Outlook

o Market Opportunistic and Attractive Investment Segment

Global Acyclovir Drug Market Segmentation:

By Product Type

• Oral
• Topical
• Injection

By Application

• HIV
• Hepatitis
• Herpes Simplex Virus
• Influenza

Some major players in the market include GlaxoSmithKline plc, Mylan NV, and Bausch Health Companies Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2021, AiCuris Anti-infective Cures AG has started Phase III development of pritelivir, a new helicase-primase inhibitor, for acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients. In November 2020, Amneal Pharmaceuticals LLC received approval for its Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. Additionally, in March 2019, Zydus Cadila gets USFDA nod to market generic tablets Acyclovir in the US.  

Geographic Coverage

o North America Market Size and/or Volume

o Latin America Market Size and/or Volume

o Europe Market Size and/or Volume

o Asia-Pacific Market Size and/or Volume

o Rest of the world Market Size and/or Volume

Key Questions Answered by Global Acyclovir Drug Market Report

1. What was the Global Acyclovir Drug Market size in 2021 and 2027; what are the estimated growth trends and market forecast (2022-2028).
2. What will be the CAGR of Global Acyclovir Drug Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Global Acyclovir Drug Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.

The report covers the following objectives:

• Proliferation and maturation of trade in the Global Acyclovir Drug market.
• The market share of the Global Acyclovir Drug market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the Global Acyclovir Drug market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the Global Acyclovir Drug market.